{"organizations": [], "uuid": "e5035349d94326c443307a5f047d20c883b0aa9d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bioverativ-and-sangamo-announce-fd/brief-bioverativ-and-sangamo-announce-fda-acceptance-of-ind-application-for-gene-edited-cell-therapy-bivv003-idUSASC0A2KF", "country": "US", "domain_rank": 408, "title": "BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-16T19:36:00.000+03:00", "replies_count": 0, "uuid": "e5035349d94326c443307a5f047d20c883b0aa9d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bioverativ-and-sangamo-announce-fd/brief-bioverativ-and-sangamo-announce-fda-acceptance-of-ind-application-for-gene-edited-cell-therapy-bivv003-idUSASC0A2KF", "ord_in_thread": 0, "title": "BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sangamo announce fda", "sentiment": "negative"}, {"name": "sangamo therapeutics inc", "sentiment": "negative"}, {"name": "sangamo therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Sangamo Therapeutics Inc:\n* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE\n* SANGAMO THERAPEUTICS - IND ENABLES BIOVERATIV TO INITIATE PHASE 1/2 CLINICAL TRIAL TO ASSESS SAFETY OF BIVV003 IN ADULTS WITH SICKLE CELL DISEASE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T19:36:00.000+03:00", "crawled": "2018-05-17T14:23:38.018+03:00", "highlightTitle": ""}